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Background: Floating-Harbor syndrome is a rare autosomal dominant short stature syndrome with retarded
speech development, intellectual disability and dysmorphic facial features. Recently dominant mutations almost
exclusively located in exon 34 of the Snf2-related CREBBP activator protein gene were identified to cause FHS.
Methods: Here we report the genetic analysis of 5 patients fulfilling the diagnostic criteria of FHS obtained by
Sanger sequencing. All of them presented with short stature, speech delay as well as psychomotor delay and
typical facial dysmorphism. Three patients showed a good response to growth hormone treatment.
Results: Two patients demonstrate novel, heterozygous de novo frameshift mutations in exon 34 (c.7396delA and
c.7218dupT) leading to premature stop mutations in SRCAP (p.Val2466Tyrfs*9 and p.Gln2407Serfs*36, respectively). In
two further patients we found already known SRCAP mutations in exon 34, c.7330C > T and c.7303C > T,
respectively, which also lead to premature stop codons: p.Arg2444* and p.Arg2435*. In one patient, we identified a
novel de novo stop mutation in exon 33 (c.6985C > T, p.Arg2329*) demonstrating that not all FHS cases are caused
by mutations in exon 34 of SRCAP.
Conclusions: Our data confirm a mutational hot spot in the final exon of SRCAP in the majority of FHS patients but
also show that exon 33 of this gene can be affected.
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Floating-Harbor syndrome (FHS, OMIM: #136140) is a
genetic disorder characterized by short stature, delayed
bone age, retarded speech development and intellectual
disability (ID) as well as characteristic facial dysmorphisms
(Figure 1).
Recently mutations located in exon 34 of the Snf2-related
CREBBP activator protein (SRCAP) gene, encoding the
core catalytic component of the multiprotein chromatin-
remodeling SRCAP complex, were found to cause FHS in
about 50 patients [1-4]. One patient who carried an exon
33 SRCAP mutation has been reported [5]. SRCAP locates* Correspondence: denise.horn@charite.de
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SRCAP is the catalytic component of the homonymous
SRCAP complex which mediates the ATP (adenosine
triphosphate)-dependent exchange of a variant histone
H2AZ/H2B dimer for a canonical H2A/H2B dimer at nu-
cleosomes, leading to transcriptional regulation of selected
genes by chromatin remodeling close to promoter regions.
SRCAP is one of several proteins that help to activate a
gene called CREBBP (Figure 2B). CREBBP plays a key role
in regulating cell growth and division and is important for
normal development. Mutations in the SRCAP gene may
result in an altered protein that interferes with normal
activation of the CREBBP gene, leading to a disturbed
development. Rubinstein-Taybi syndrome, an autosomal
dominant inherited disorder with some phenotypic overlap,
is caused by mutations in the CREBBP gene itself [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Photographs of patients, showing facial characteristics of Floating-Harbor syndrome. A - Patient A at age 5 years. B - Patient B
at 22 years. C - Patient C at 5.5 years. D - Patient D at 7 years. E - Patient E at age of 5.5 years. Note overlapping facial dysmorphisms such as
long-hanging columella, short philtrum, and thin lips.
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patients fulfilling the diagnostic criteria of FHS. All of
them presented with short stature, speech as well as
psychomotor delay and typical facial dysmorphism in-
cluding a prominent nose, low-hanging columella and
short philtrum.Figure 2 Schematic representation of the SRCAP gene and positions o
have been identified to cause FHS (red frame – novel mutations, red-gray
network predicted functional links to several proteins involved in transc
including CREBBP.Methods
Patients
Written informed consent forms and permission for
publication of this report and accompanying photo-
graphs were obtained from all participants or their legal
guardians.f known SRCAP mutations. A - In this study, five de novo mutations
dashed frame – recurrent mutations). B - Expanded SRCAP protein
riptional regulation of selected genes by chromatin remodeling
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Mutation analysis
Genomic DNA was isolated from peripheral blood using
standard techniques. For mutation screening we amplified
the coding region of SRCAP [NCBI Reference Sequence:
NM_006662.2], including the flanking intronic sequences
and the predicted promoter region. Primer sequences and
PCR (polymerase chain reaction) conditions are available
on request. PCR products were purified using the enzymes
exonuclease I and shrimp alkaline phosphatase treatment,
and directly sequenced with the BigDye™ Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) and
analyzed on an automated DNA Analyzer (3730 Applied
Biosystems).Table 1 Summary of clinical and molecular data of patients w
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*The clinical manifestations of patient B at age of 5 years were published in the AJMProtein network analysis
An expanded protein network of SRCAP was created
by the STRING interaction database (string-db.org).
As parameters for the network display were used ‘evi-
dence view’, ‘high confidence 0.700’, and ‘no more than
10 interactors’.
Results
All patients demonstrated heterozygous de novo muta-
tions in the gene SRCAP (Table 1, Figure 2A). For patients
A and B, we identified two novel frameshift mutations
in exon 34 (c.7396delA and c.7218dupT, respectively)
predicted to introduce premature stop codons in SRCAP
(p.Val2466Tyrfs*9 and p.Gln2407Serfs*36, respectively).
Patients C and D carry previously described point muta-
tions c.7330C > T and c.7303C > T, respectively, which alsoith Floating-Harbor syndrome
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[1,2]. Interestingly, in patient E, Sanger sequencing identi-
fied a novel stop mutation in exon 33 (c.6985C > T,
p.Arg2329*) (Figure 2B, red-framed boxes).
Table 1 and Figure 1 summarize the clinical data. In
the individuals analyzed here birth weights ranged be-
tween mean and -1.3 SD (standard deviation) as well as
birth lengths between -1 to -2 SD (Table 1). The occipi-
tofrontal head circumference (OFC) at birth was normal
in all. Prior puberty bone ages were significantly delayed
when X-rays were available (in patients A, B, C, D).
Postnatal short stature varied from -1.7 to -3.7 SD, how-
ever three patients (patients A, B, E) received growth
hormone (GH) therapy during childhood and their
heights were between -1.7 to -2 SD at time of last assess-
ment. In all individuals, postnatal OFC was lower than
the mean but still in the normal range (-0.4 to -1.7 SD).
Delayed pubertal development and primary ovarian in-
sufficiency were observed in patient B. Patient C showed
normal pubertal development and hypermenorrhoea in
adult age.
Behavioral difficulties such us aggressive behavior, anx-
iety, sleep disturbances, and rigid mannerisms were ob-
served in two patients starting before and at puberty
(patients A and E) and in adulthood (patient C), respect-
ively. Except one, all patients showed delayed speech de-
velopment as well as reduced cognitive abilities with
schooling at schools for mentally handicapped children.
As adults two patients were able to speak in short sen-
tences and to read and write with simple skills. Patient E
carrying the exon 33 mutation showed only mild speech
delay but has normal cognitive skills and attended a nor-
mal school.
The characteristic facial aspect with a prominent nose
with a broad nasal tip, a low hanging columella, a short
philtrum, and a thin upper lip was present in all and re-
mains constant also in adult patients (Figure 1). Minor
skeletal abnormalities such us brachydactyly (patients A,
B, D), broad fingertips (patients C and E) or pseudoar-
throsis of the clavicles (patient C) were observed in all
patients studied here.
Discussion
Our molecular data confirm a mutational hot spot in the
final exons of SRCAP in all patients tested here. Postnatal
short stature with in relation larger OFC together with a
distinct facial aspect and delayed speech development as
important diagnostic criteria of FHS were fulfilled in all
patients reported here. Markedly delayed bone age was
disclosed in all patients (A, B, C, D) where hand radio-
grams were available. Behavioral difficulties were observed
in three patients of our study group and occur in about
one third in a larger study cohort, therefore behavioral
problems should be monitored [4]. Interestingly, growthhormone treatment led to significant growth improve-
ment toward the low normal range in three patients in-
dicating effectiveness of this therapy in patients with
FHS. One female patient with the clinical diagnosis of
FHS has been reported with precocious puberty follow-
ing treatment with gonadotrophin-releasing hormone
analogue and later growth hormone treatment because
of growth hormone deficiency [7]. This patient reached
average adult height.
So far unreported endocrinological abnormalities
(delayed puberty and primary ovarian insufficiency in pa-
tient B and hypermenorrhoea in patient C) were docu-
mented in the adult females reported here.
The vast majority of affected individuals carries truncat-
ing mutations of exon 34 of SRCAP with two mutations
(p.Arg2444*, p.Arg2435*) which are recurrently identified
(Figure 2A) [1,3,4]. In our cohort we identified these two
recurrent mutations and two novel frameshift mutations
in exon 34. Moreover, we found one novel mutation in the
penultimate exon 33. The phenotype of this patient is in
accordance with the manifestations of FHS, except for ID.
Interestingly, she is the only one in our cohort with only
mild speech delay and normal schooling. One could
speculate that this milder phenotype may be due to partial
nonsense-mediated decay or faster degradation of the pro-
duced altered SRCAP protein. Until now, only one other
mutation in exon 33 of SRCAP (p.Gln2334*) has been
documented in an affected individual with typical features
of FHS [5]. Apart from typical manifestations of FHS this
8 year old patient has not only speech delay but also signifi-
cant intellectual disability in contrast to our patient carrying
the exon 33 mutation. However, average intelligence and
regular schooling have been already reported in a few af-
fected individuals with exon 34 mutations and therefore
the broad range of cognitive skills in patients with FHS
seems to include normal psychomotor development [4].
All hitherto FHS causing mutations are predicted to
cause a truncated SRCAP protein lacking the putative
C-terminal AT-hook DNA binding motif. Due to the ob-
served heredity transmission by heterozygous de novo
mutation a dominant negative disease mechanism has
been postulated [1]. Therefore, truncating mutations out-
side exons 34 and 33 may result in nonsense mediated
decay leading to different phenotypic effects [8]. One ex-
ample of different phenotypes associated with mutations
located in the last exons of a gene versus mutations in
other exons is a lipodystrophy-progeroid phenotype in in-
dividuals carrying mutations in the last exon of the FBN1
gene while mutations of other exons of this gene lead to
Marfan syndrome [9]. However, absence of SRCAP muta-
tions were reported in 3/9 patients investigated by direct
sequencing and may have different explanations, e.g. an
overlapping phenotypic spectrum with Rubinstein-Taybi
syndrome or other syndromes as well as possible genetic
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include proteins in distinct vicinity to SRCAP and CREBBP
with functional links to chromatin remodeling mechanisms
(Figure 2B). Thus, further work is required to fully elucidate
the pathomechanism of FHS.
Conclusions
In patients with suspected FHS, we strongly recommend
that mutational analysis should include not only sequence
analysis of exon 34 but should extend to at least exon 33
of this gene. Growth hormone treatment shows effective-
ness in patients with FHS.
Endocrinological and gynaecological follow-up is needed
for adult patients with FHS to evaluate for further
complications.
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